Biology subjects

Roos, W. P.

Publications and source records attributed to Roos, W. P..

3 recordsLinked to original sources

bioRxiv2026

HIPK2 regulates homology-directed DNA repair and PARP inhibitor sensitivity

Repair of DNA double-strand breaks (DSBs) by homologous recombination (HR) counteracts genome instability and carcinogenesis. Cancer cells frequently show defects in HR which can be therapeutically exploited by hypersensitivity to poly(ADP-ribose) polymerase inhibitor (PARPi) treatment. Here we identify an unforeseen function of HIPK2 in HR repair and PARPi sensitivity. HIPK2 accumulates at DSBs and associates with DSB repair factors at DNA damage foci. DSB recruitment of HIPK2 requires checkpoint kinase ATM activity. DNA repair pathway analysis revealed that HIPK2 depletion specifically impairs HR. Mechanistically, we found that HIPK2 binds BRCA1 and phosphorylates BRCA1 at Ser1191, a site that regulates damage-induced BRCA1 protein stability. Consistently, HIPK2 depletion or pharmacological inhibition of HIPK2 results in reduced BRCA1 protein levels, and sensitizes BRCA1-proficient cancer cells to IR damage and PARPi treatment. In sum, our results identify a role for HIPK2 in HR through regulating BRCA1 protein levels, and propose HIPK2 inhibition as a novel strategy to sensitize BRCA1-proficient cancer cells to PARPi treatment.

cell biology↗

bioRxiv2025

DNA polymerase beta expression in head & neck cancer modulates the poly(ADP-ribose)-mediated replication checkpoint

Head and Neck Squamous Cell Carcinoma (HNSCC) imposes a significant health burden, necessitating innovative therapeutic strategies to enhance treatment efficacy. Current treatments such as surgery, radiation, and chemotherapy have limited effectiveness and yield severe side effects, emphasizing the need for targeted therapies. We have focused on DNA polymerase beta (Pol{beta}) and its roles in replication stress, cellular responses to DNA damaging therapies, and DNA damage response modifiers. Our investigations reveal a regulatory role for base excision repair (BER) proteins, including Pol{beta}, in the cellular response to inhibitors of poly(ADP-ribose) glycohydrolase (PARG), an enzyme involved in poly(ADP-ribose) (PAR) degradation. The inhibition of PARG, in HNSCC cells, elicits replication stress. Further, this activates the PAR-induced S-phase/ATR checkpoint, leading to a block to replication, cell cycle arrest, and the onset of apoptosis. However, Pol{beta} overexpression mitigates this response, reducing replication-stress induced PAR foci formation, suggesting a modulation of replication checkpoint activation. We found that PARG inhibitor treatment is ineffective on HNSCC cells that overexpress Pol{beta}, implying that the PARG inhibitor-induced PAR and apoptotic response is dependent on the level of Pol{beta}. Further, our in vitro experiments demonstrate that combining PARG and ATR/CHK1 inhibitors overcomes Pol{beta}-mediated treatment resistance in HNSCC cells, producing enhanced effects as compared to the individual treatment conditions. Our findings suggest a possible treatment paradigm for HNSCC, employing ATR or CHK1 inhibitors in combination with PARG inhibitors. This strategy offers a promising path for more effective HNSCC treatments, potentially overcoming Pol{beta}-related resistance.

cancer biology↗

bioRxiv2022

Epigenetic anti-cancer treatment with a stabilized carbocyclic Decitabine analogue

5-Aza-2-deoxycytidine (Decitabine, AzadC) is a nucleoside analogue, which is in clinical use to treat patients with myelodysplastic syndrome or acute myeloid leukemia. Its mode of action is unusual because the compound is one of the few drugs that act at the epigenetic level of the genetic code. AzadC is incorporated as an antimetabolite into the genome and creates covalent, inhibitory links to DNA methyltransferases (DNMTs) that methylate 2-deoxycytidine (dC) to 5-methyl-dC (mdC). Consequently, AzadC treatment leads to a global loss of mdC, which presumably results in a reactivation of silenced genes, among them tumor suppressor and DNA damage response genes. Because AzadC suffers from severe instability, which limits its use in the clinic, a more sophisticated AzadC derivative would be highly valuable. Here, we report that a recently developed carbocyclic AzadC analogue (cAzadC) blocks DNMT1 in the AML cell line MOLM-13 as efficient as AzadC. Moreover, cAzadC has a surprisingly strong anti-proliferative effect and leads to a significantly higher number of double strand breaks compared to AzadC, while showing less off-target toxicity. These results show that cAzadC triggers more deleterious repair and apoptotic pathways in cancer cells than AzadC, which makes cAzadC a promising next generation epigenetic drug.

cancer biology↗